Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 208 participants
Moderate